Ivermectin ineffective in large study of treatment among patients with Covid-19
On Mar. 31, 2022, researchers in Brazil reported that a study of COVID-19 patients at 12 clinics that…
-
-
Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
-
Researchers generated the first complete, gapless sequence of a human genome
On Mar. 31, 2022, researchers announced they have created a complete, gap-free sequence of the roughly 3 billion…
-
Lucira’s COVID-19 & flu at-home molecular test showed Positive clinical trial results
On Mar. 30, 2022, Lucira Health announced that preliminary clinical trial results for its candidate COVID-19 & Flu…
-
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech received expanded U.S. EUA for additional COVID-19 vaccine booster in individuals Aged 50 Years and older
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
-
Pfizer supplied UNICEF 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-Income countries
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
-
Twist Bioscience launched synthetic RNA positive controls for SARS-CoV-2 encapsulated in imagene’s stainless steel capsules
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
-
Genomics | NIH | Therapeutics
NIH’s All of Us Research program released first genomic dataset of nearly 100,000 whole genome sequences
On Mar. 17, 2022, the National Institutes of Health announced that nearly 100,000 highly diverse whole genome sequences…
-
Soligenix COVID-19 vaccine, CiVax, boosted neutralizing activity against SARS-CoV-2, including Delta and Omicron
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax™ (heat stable COVID-19…
-
Cocrystal Pharma initiated enrollment in phase 1 influenza a study with novel, broad-spectrum, orally administrated antiviral CC-42344
On Mar. 10, 2022, Cocrystal Pharma announced dosing of the first subjects in a Phase 1 clinical trial…
-
Mandatory masking in schools reduced COVID-19 cases during Delta surge
On Mar. 10, 2022, schools with mandatory masking during the Delta surge had approximately 72% fewer cases of…
-
Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease…
-
CDC reported disparities in COVID-19 vaccination coverage between urban and rural counties
On Mar. 4, 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that COVID-19 vaccination coverage with…
-
COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine | WHO
WHO and MPP welcomed NIH’s offer of COVID-19 health technologies to C-TAP
On Mar. 3, 2022, the World Health Organization (WHO) and the Medicines Patent Pool (MPP) jointly welcomed the announcement…
-
Possible case of deer-to-human SARS-CoV-2 transmission
On Mar. 3, 2022, a study carried out in southwestern Ontario identified a highly mutated variant of SARS-CoV-2…
-
Roche announced donation of essential medicines to Ukraine
On Mar. 2, 2022, Roche announced an initial donation of essential medicines to Ukraine. Roche is working diligently…
-
Agriculture | Biotechnology | Diagnostics | Disease | Infectious Disease | Influenza | Therapeutics | USDA | Vaccine
Iowa Department of Agriculture and USDA Confirm Case of Highly Pathogenic Avian Influenza in Non-Commercial Backyard Flock
On Mar. 2, 2022, the Iowa Department of Agriculture and Land Stewardship and the United States Department of…
-
Biotechnology | COVID-19 | FDA | Therapeutics
Sorrento announced FDA authorization to proceed with phase 1 study of Intranasal STI-9199 against Covid-19 viruses
On Mar. 2, 2022, Sorrento Therapeutics announced that its Phase I study of intranasal (IN) STI-9199 (COVISHIELDTM IN) has…
-
Biotechnology | CRISPR | Disease | Genomics | Therapeutics
U.S. patent appeal board ruled against University of California in CRISPR interference
On Feb. 28, 2022, the Patent and Trial Appeal Board of the U.S. Patent and Trademark Office (USPTO)…
-
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine | WHO
Sorrento announced COVISHIELD antibody strongly neutralized BA.2 Omicron sublineage virus
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
-
The University of Virginia Cancer Center Received NCI Comprehensive Designation
On Feb. 1, 2022, University of Virginia Cancer Center announced it had been awarded a Comprehensive Cancer Center…
-
Scientists pinpointed mechanisms associated with severe COVID-19 blood clotting
On Feb. 17, 2022, after studying blood samples from 244 patients hospitalized for COVID-19, a group of researchers,…
-
Resverlogix expanded phase 2b clinical trial for COVID-19 treatment with first site in Brazil and second in Canada
On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b…
-
Researchers documented third known case of HIV remission involving stem cell transplant
On Feb. 15, 2022, a woman with HIV who received a cord blood stem cell transplant to treat…
-
China approved use of Pfizer’s COVID drug Paxlovid
On Feb. 12, 2022, China’s medical products regulator announced that it had given conditional approval for Pfizer’s COVID-19…
-
Gilead reported phase 2/3 interim data evaluating safety, tolerability and clinical outcomes of Veklury (Remdesivir) in pediatric patients with COVID-19
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
-
Veklury (Remdesivir) retained antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
-
Biotechnology | COVID-19 | NIH | Therapeutics
Merck and Ridgeback announced 3.1 million courses of molnupiravir investigational oral antiviral COVID-19 medicine supplied to U.S. Government
On Feb. 8, 2022, Merck and Ridgeback Biotherapeutics announced that a total of 3.1 million courses of molnupiravir,…
-
Biotechnology | COVID-19 | Influenza | Plague | Therapeutics
NIAID Pandemic Preparedness Plan targeted ‘prototype’ and priority pathogens
On Feb. 2, 2022, NIAID scientists announced the new Pandemic Preparedness Plan aimed to support critical basic and…
-
Study of Penn patients with decade-long leukemia remissions after CAR T cell therapy revealed new details about persistence of personalized ‘Living Drug’ cells
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
